Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
M Górecki, I Kozioł, A Kopystecka, J Budzyńska… - Biomedicines, 2023 - mdpi.com
The KMT2A (formerly MLL) encodes the histone lysine-specific N-methyltransferase 2A and
is mapped on chromosome 11q23. KMT2A is a frequent target for recurrent translocations in …
is mapped on chromosome 11q23. KMT2A is a frequent target for recurrent translocations in …
Therapeutic targeting of the leukaemia microenvironment
V Kuek, AM Hughes, RS Kotecha… - International journal of …, 2021 - mdpi.com
In recent decades, the conduct of uniform prospective clinical trials has led to improved
remission rates and survival for patients with acute myeloid leukaemia and acute …
remission rates and survival for patients with acute myeloid leukaemia and acute …
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal
prognosis. Survival outcomes have remained static in recent decades despite treatment …
prognosis. Survival outcomes have remained static in recent decades despite treatment …
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia
High-risk childhood leukemia has a poor prognosis because of treatment failure and toxic
side effects of therapy. Drug encapsulation into liposomal nanocarriers has shown clinical …
side effects of therapy. Drug encapsulation into liposomal nanocarriers has shown clinical …
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia
KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory
type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we …
type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we …
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
Rearrangments in Histone-lysine-N-methyltransferase 2A (KMT2Ar) are associated with
pediatric, adult and therapy-induced acute leukemias. Infants with KMT2Ar acute …
pediatric, adult and therapy-induced acute leukemias. Infants with KMT2Ar acute …
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Acute leukemia continues to be a major cause of death from disease worldwide and current
chemotherapeutic agents are associated with significant morbidity in survivors. While better …
chemotherapeutic agents are associated with significant morbidity in survivors. While better …
The role of proteasome inhibitors in treating acute lymphoblastic leukaemia
C Sin, PM Man - Frontiers in Oncology, 2021 - frontiersin.org
Acute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The
prognosis of ALL is excellent in paediatric population, however the outcome of …
prognosis of ALL is excellent in paediatric population, however the outcome of …
The combination of curaxin CBL0137 and histone deacetylase inhibitor panobinostat delays KMT2A-rearranged leukemia progression
Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in
approximately 10% of acute leukemias and characteristically define disease with poor …
approximately 10% of acute leukemias and characteristically define disease with poor …
Defining the fetal origin of MLL-AF4 infant leukemia highlights specific fatty acid requirements
V Symeonidou, H Jakobczyk, S Bashanfer, C Malouf… - Cell reports, 2021 - cell.com
Infant MLL-AF4-driven acute lymphoblastic leukemia (ALL) is a devastating disease with
dismal prognosis. A lack of understanding of the unique biology of this disease, particularly …
dismal prognosis. A lack of understanding of the unique biology of this disease, particularly …